Back to Feed
Fintech
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
Globenewswire·
With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one...
Original Source
Globenewswire — www.globenewswire.com